| HOME >> MEDICINE >> TECHNOLOGY |
(21)
(0.01)(21)
(0.01) *Amortization expense
271
0.18304
0.20 *Adjusted net income$ 822$
.54$
737$
.48* Assumes dilution of 9.2 million shares for the nine months ended September 30, 2010 for all or a portion of these non-GAAP adjustments.
An explanation of the Company's use of these non-GAAP financial measures is provided at the end of this document.
BOSTON SCIENTIFIC CORPORATIONNON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS (CONT.)
(Unaudited)Three Months EndedNine Months Endedin millions
September 30,September 30,2011201020112010Goodwill impairment net charges:Goodwill impairment net charges$
97
$ 1,817Income tax benefit (a)Goodwill impairment net charges, net of tax$
97$ 1,817Intangible asset impairment charges:Intangible asset impairment charges
$
9
$
5$
21
$
5Income tax benefit (a)(2)
(1)(5)
(10)Intangible asset impairment charges, net of tax
$
7$
4$$
55Acquisition-related net charges (credits):Contingent consideration expense
$$
8Acquisition-related milestone$
(250)Acquisition-related costs (b)13Inventory step-up adjustment (c)12Gain on previously held equity interests (e)(38)8(15)
(250)Income tax (benefit) expense (a)(1)(2)
34Acquisition-related net charges (credits), net of tax
$
7$
(17)$
(216)Divestiture-related net credits:Gain on divestiture
$
(8)$ (768)Divestiture-related costs (d)14(7)(764)Income tax expense (a)2231Divestiture-related net credits, net of tax
$
(5)$ (533)Restructuring-related charges:Restructuring charges
$ 22
$
5$
77
$
98Restructuring-related charges (f)7
1332
4129
18109
139Income tax benefit (a)(10)<
'/>"/>
| SOURCE Boston Scientific Corporation Copyright©2010 PR Newswire. All rights reserved |